Stephen Chitty, MD
Pulmonary Disease · Brunswick, GANPI 1902895824
Payments from drug & device makers
Across 1,164 payments — averaging $25.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- AstraZeneca$3K
- GSK$3K
- Sanofi$2K
- Regeneron Healthcare Solutions, Inc.$2K
- Grifols USA, LLC$1K
- plus $13K from 54 others
What the payments were for
- Consulting fees$530%
- Travel & lodging$1611%
- Food & beverage$23,26278%
- Education$6,51122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$6,000
- DUPIXENT$1,075
- FASENRA$388
- TEZSPIRE$323
- AIRSUPRA$165
- Da Vinci Surgical System$155
- MeMed BV Calibrator$153
- ILLUMISITE$152
- Inspire Upper Airway Stimulation System$128
- MONARCH$127
- Spin$118
- CHARTIS CATHETER$111
- ZEPHYR DELIVERY CATHETER$111
- ZEPHYR ENDOBRONCHIAL VALVE$111
- PULMONX CHARTIS TABLET CONSOLE$111
- FARXIGA$110
- BREZTRI$110
How this compares
$29,987 in reported general payments places this provider in the 80th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 38 | $499,158 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 490 | $418,914 |
| NucalaMepolizumab | 108 | $399,965 |
| Dupixent PenDupilumab | 80 | $330,798 |
| AdempasRiociguat | 20 | $326,723 |
| OfevNintedanib Esylate | 18 | $233,938 |
| Breo ElliptaFluticasone/Vilanterol | 386 | $164,967 |
| Sodium Oxybate | 12 | $152,853 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 150 | $125,327 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 24 | $115,149 |
| Dupixent SyringeDupilumab | 27 | $103,263 |
| SymbicortBudesonide/Formoterol Fumarate | 311 | $89,297 |
| TezspireTezepelumab-Ekko | 21 | $83,345 |
| XolairOmalizumab | 53 | $74,507 |
| Fasenra PenBenralizumab | 13 | $72,856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $2,803 | $1,062,3701,155 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $863 | $499,15838 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $1,121 | $338,768190 claims |
| BayerAdempas | $175 | $326,72320 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Tezspire, Bevespi Aerosphere | $3,117 | $303,888496 claims |
| CSL BehringHizentra | $350 | $115,14924 claims |
| PfizerEliquis | $312 | $55,79286 claims |
| Johnson & JohnsonXarelto | $277 | $14,21316 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $37 | $7,97529 claims |
| MerckDulera | $217 | $3,39811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Brunswick
- Maria MascoloRincon$2.7M
- Chad MillerAustell$2M
- Amy CaseAustell$1.5M
- Srihari VeeraraghavanAtlanta$1.3M
- Jose MedinaValdosta$1.3M
- Micah FisherAtlanta$1.2M
- Frances LeeAtlanta$1.2M
- Vijay PatelNewnan$1.1M
- Lawrence McDermottSavannah$963K
- Ngozika OrjiokeEast Point$846K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.